MDM2 and non-small cell lung carcinoma: Multiple CGP ICPI biomarkers were present in the NSCLC-BM cohort: TMB-High (55.40%, 1680/3035); MSI-H (0.70%, 22/3035), CD274 amplifications (1.5%, 47/3035); STK11 mutations (17.70%, 538/3035); KEAP1 mutations (8.90%, 271/3035); MDM2 amplifications (3.30%, 100/3035); MDM4 amplifications (0.80%, 24/3035); and APOBEC mutational signature (6.00%, 182/3035).